Phase I Study of Bortezomib (Velcade) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Mesna; Methotrexate; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 10 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
- 10 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
- 14 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.